|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts Receivable | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts Payable and Accrued Expenses | ||||||||||||||||||||
| Accrued Board of Director/Officer Compensation | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Common Stock - $0.001 Par; 850,000,000 Shares Authorized, 238,216,969 Issued and Outstanding | ||||||||||||||||||||
| Additional Paid-In-Capital | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Total Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity (Deficit) | ||||||||||||||||||||
Loading...
